Cytorhodin A
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03038 |
| CAS | 95599-38-5 |
| Molecular Weight | 1157.34 |
| Molecular Formula | C60H88N2O20 |
Online Inquiry
Description
It is an anthracycline antibiotic produced by the strain of Streptomyces cyaneus (A-447). It can inhibit the growth of P388 murine lymphocytic leukemia cells with IC50 of 2.9 ng/mL.
Specification
| Synonyms | 1-Deoxyobelmycin B; A-447C; Antibiotic A-447C; 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-7,10-bis[[2,3,6-trideoxy-3-(dimethylamino)-4-O-[(2S,5S,6S)-tetrahydro-6-methyl-5-[[(2S,5S,6S)-tetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl]oxy]-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)-; [7R-(7a,8b,10b)]-8-Ethyl-7,8,9,10-tetrahydro-1,6,8,11-tetrahydroxy-7,10-bis[[2,3,6-trideoxy-3-(dimethylamino)-4-O-[[2S-[2a,5b(2R*,5R*,6R*),6b]]-tetrahydro-6-methyl-5-[(tetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl)oxy]-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione |
| IUPAC Name | (7S,9R,10R)-7,10-bis[[(2S,4S,5S,6S)-4-(dimethylamino)-5-[(2S,5S,6S)-5-[(2S,5S,6S)-5-hydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy]-9-ethyl-4,6,9,11-tetrahydroxy-8,10-dihydro-7H-tetracene-5,12-dione |
| Canonical SMILES | CCC1(CC(C2=C(C1OC3CC(C(C(O3)C)OC4CCC(C(O4)C)OC5CCC(C(O5)C)O)N(C)C)C(=C6C(=C2O)C(=O)C7=C(C6=O)C=CC=C7O)O)OC8CC(C(C(O8)C)OC9CCC(C(O9)C)OC1CCC(C(O1)C)O)N(C)C)O |
| InChI | InChI=1S/C60H88N2O20/c1-12-60(70)26-41(79-46-24-34(61(8)9)57(31(6)75-46)80-44-22-18-39(29(4)73-44)77-42-20-16-36(63)27(2)71-42)49-52(56(69)50-51(55(49)68)54(67)48-33(53(50)66)14-13-15-38(48)65)59(60)82-47-25-35(62(10)11)58(32(7)76-47)81-45-23-19-40(30(5)74-45)78-43-21-17-37(64)28(3)72-43/h13-15,27-32,34-37,39-47,57-59,63-65,68-70H,12,16-26H2,1-11H3/t27-,28-,29-,30-,31-,32-,34-,35-,36-,37-,39-,40-,41-,42-,43-,44-,45-,46-,47-,57+,58+,59+,60+/m0/s1 |
| InChI Key | JCVKGZNZMVGUIP-ODLVGNROSA-N |
Properties
| Appearance | Red Powder |
| Antibiotic Activity Spectrum | Neoplastics (Tumor) |
| Melting Point | 192-195°C (dec.) |
| Density | 1.37 g/cm3 |
| Solubility | Soluble in Methanol |
Reference Reading
1. CytA, a reductase in the cytorhodin biosynthesis pathway, inactivates anthracycline drugs in Streptomyces
Chun Gui, Jiang Chen, Qing Xie, Xuhua Mo, Shanwen Zhang, Hua Zhang, Junying Ma, Qinglian Li, Yu-Cheng Gu, Jianhua Ju Commun Biol. 2019 Dec 6;2:454. doi: 10.1038/s42003-019-0699-5. eCollection 2019.
Antibiotic-producing microorganism can develop strategies to deal with self-toxicity. Cytorhodins X and Y, cosmomycins A and B, and iremycin, are produced as final products from a marine-derived Streptomyces sp. SCSIO 1666. These C-7 reduced metabolites show reduced antimicrobial and comparable cytotoxic activities relative to their C-7 glycosylated counterparts. However, the biosynthetic mechanisms and relevant enzymes that drive C-7 reduction in cytorhodin biosynthesis have not yet been characterized. Here we report the discovery and characterization of a reductase, CytA, that mediates C-7 reduction of this anthracycline scaffold; CytA endows the producer Streptomyces sp. SCSIO 1666 with a means of protecting itself from the effects of its anthracycline products. Additionally, we identified cosmomycins C and D as two intermediates involved in cytorhodin biosynthesis and we also broadened the substrate specificity of CytA to clinically used anthracycline drugs.
2. Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil
F W Busch, U Schmittele, G Ehninger Blut. 1990 Apr;60(4):219-22. doi: 10.1007/BF01728787.
Drug-induced myelotoxicity is usually the dose-limiting factor of treatment of malignant tumors with cytostatic drugs. Suppression of in vitro myelopoiesis (CFU-GM) by cytostatics may be a suitable model reflecting the in vivo situation. Thus the inhibitory effects of the anthracyclines doxorubicin, theprubicin, idarubicin and cytorhodin S on CFU-GM were compared. Normal human bone marrow cells were incubated with these drugs for one hour and alternatively, for the whole culture period. For each substance and each incubation time a dose-response curve was established and the D50 determined. As certain calcium antagonists can increase the toxicity of some cytostatic drugs in various tumor models, the effect of the addition of verapamil (2 microM) was also investigated. It could be shown, that the myelotoxicity on CFU-GM of the drugs mentioned above was not increased after short-term or permanent exposure to this calcium antagonist.
3. Elucidating the Sugar Tailoring Steps in the Cytorhodin Biosynthetic Pathway
Chun Gui, Xuhua Mo, Yu-Cheng Gu, Jianhua Ju Org Lett. 2017 Oct 20;19(20):5617-5620. doi: 10.1021/acs.orglett.7b02758. Epub 2017 Oct 3.
Anthracycline antitumor cytorhodins X and Y feature a rare 9α-glycoside and 7-dexoy-aglycone. Characterization of the cytorhodin gene cluster from Streptomyces sp. SCSIO 1666 through gene inactivations and metabolite analyses reveals three glycosyltransferases (GTs) involved in the sugar tailoring steps. The duo of CytG1 and CytL effects C-7 glycosylation with l-rhodosamine whereas the iterative GT CytG3 and CytW similarly modifies both C-9 and C-10 positions. CytG2 also acts iteratively by incorporating the second and third sugar moiety into the trisaccharide chains at the C-7 or C-10 position.
Recommended Products
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-03754 | Castanospermine | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
